Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection

Kim, Min‐Chul; Lee, Jeong Woo; Choi, Hyo-Jick; Lee, Yuna; Hwang, Hye Suk; JongSang, Lee; Kim, Cheol; Lee, Jong Seok; Montemagno, Carlo; Prausnitz, Mark R.; Kang, Sang‐Moo

doi:10.1016/j.jconrel.2015.05.278

Cited by 49 publications

(48 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…showed that heterologous VLPs incorporating the influenza virus M2 extracellular domain generated a broad cross-protective effect against H1N1, H3N2, and H5N1. 184 …”

Section: Transcutaneous Vaccinationmentioning

confidence: 99%

Noninvasive vaccination against infectious diseases

Zheng

Díaz-Arévalo

Guan

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The development of a successful vaccine, which should elicit a combination of humoral and cellular responses to control or prevent infections, is the first step in protecting against infectious diseases. A vaccine may protect against bacterial, fungal, parasitic, or viral infections in animal models, but to be effective in humans there are some issues that should be considered, such as the adjuvant, the route of vaccination, and the antigen-carrier system. While almost all licensed vaccines are injected such that inoculation is by far the most commonly used method, injection has several potential disadvantages, including pain, cross contamination, needlestick injury, under- or overdosing, and increased cost. It is also problematic for patients from rural areas of developing countries, who must travel to a hospital for vaccine administration. Noninvasive immunizations, including oral, intranasal, and transcutaneous administration of vaccines, can reduce or eliminate pain, reduce the cost of vaccinations, and increase their safety. Several preclinical and clinical studies as well as experience with licensed vaccines have demonstrated that noninvasive vaccine immunization activates cellular and humoral immunity, which protect against pathogen infections. Here we review the development of noninvasive immunization with vaccines based on live attenuated virus, recombinant adenovirus, inactivated virus, viral subunits, virus-like particles, DNA, RNA, and antigen expression in rice in preclinical and clinical studies. We predict that noninvasive vaccine administration will be more widely applied in the clinic in the near future.

show abstract

“…showed that heterologous VLPs incorporating the influenza virus M2 extracellular domain generated a broad cross-protective effect against H1N1, H3N2, and H5N1. 184 …”

Section: Transcutaneous Vaccinationmentioning

confidence: 99%

Noninvasive vaccination against infectious diseases

Zheng

Díaz-Arévalo

Guan

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…To prepare “out-of-plane” MN, stainless steel MN were first manually pushed out of the sheet using either forceps or a hypodermic needle and then bent at 90° angle with the aid of a single-edged razor blade. Stainless steel microneedles can also be made by wet-etching photolithographically defined needle structures from stainless steel sheets [ 30 ]. The authors used these MN to deliver a vaccine based on virus-like particles containing influenza virus heterologous M2 extracellular (M2e) domains (M2e5xVLPs).…”

Section: Solid Microneedlesmentioning

confidence: 99%

Transdermal Delivery of Drugs with Microneedles—Potential and Challenges

2015

View full text Add to dashboard Cite

Transdermal drug delivery offers a number of advantages including improved patient compliance, sustained release, avoidance of gastric irritation, as well as elimination of pre-systemic first-pass effect. However, only few medications can be delivered through the transdermal route in therapeutic amounts. Microneedles can be used to enhance transdermal drug delivery. In this review, different types of microneedles are described and their methods of fabrication highlighted. Microneedles can be fabricated in different forms: hollow, solid, and dissolving. There are also hydrogel-forming microneedles. A special attention is paid to hydrogel-forming microneedles. These are innovative microneedles which do not contain drugs but imbibe interstitial fluid to form continuous conduits between dermal microcirculation and an attached patch-type reservoir. Several microneedles approved by regulatory authorities for clinical use are also examined. The last part of this review discusses concerns and challenges regarding microneedle use.

show abstract

“…The efficacy of influenza VLP vaccines via MN skin route was higher than that with IM immunization by enabling dose-sparing effects and rapid recall immune responses [21–23]. In addition, microneedle-based immunization using influenza VLP vaccines could have logistic advantages associated with avoidance of hypodermic needles and syringes, potential for rapid distribution and administration of microneedle patches, indicating a great impact on improving vaccination efficacy, coverage, and public health.…”

Section: Influenza Vlp Vaccines Conferring Protection Against Homomentioning

confidence: 99%

Progress in developing virus-like particle influenza vaccines

Quan

Lee

Kim

et al. 2016

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

Summary Recombinant vaccines based on virus-like particles (VLPs) or nanoparticles have been successful in their safety and efficacy in preclinical and clinical studies. The technology of expressing enveloped VLP vaccines has combined with molecular engineering of proteins in membrane-anchor and immunogenic forms mimicking the native conformation of surface proteins on the enveloped viruses. This review summarizes recent developments in influenza VLP vaccines against seasonal, pandemic, and avian influenza viruses from the perspective of use in humans. The immunogenicity and efficacies of influenza VLP vaccine in the homologous and cross-protection were reviewed. Discussions include limitations of current influenza vaccination strategies and future directions to confer broadly cross protective new influenza vaccines as well as vaccination.

show abstract

Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection

Cited by 49 publications

References 49 publications

Noninvasive vaccination against infectious diseases

Noninvasive vaccination against infectious diseases

Transdermal Delivery of Drugs with Microneedles—Potential and Challenges

Progress in developing virus-like particle influenza vaccines

Contact Info

Product

Resources

About